logo-loader

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Published: 13:24 12 Mar 2019 EDT

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021.

Zynerba is on track to report top-line results from tests of its Zygel, a CBD gel treatment for children and adolescents with Fragile X syndrome. Anido says the results are expected by the second half of 2019.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

3 hours, 51 minutes ago